ANIK Q3 2023 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q3 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$41M+3.0% YoY

Gross Profit

$25M60.2% margin

Operating Income

-$8M-18.5% margin

Net Income

-$7M-15.9% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

-6.4%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$6M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$328M

Total Liabilities

$58M

Stockholders' Equity

$270M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$40M	+3.0%
Gross Profit	$25M	$23M	+9.5%
Operating Income	-$8M	-$6M	-32.4%
Net Income	-$7M	-$4M	-57.5%

Revenue Segments

Joint Preservation and Restoration

$13M81%

Non-Orthopedic

$3M19%

Geographic Segments

UNITED STATES

$31M85%

Europe

$5M15%